Finasteride
NDC Package 51079-321-56

The code 51079-321-56 identifies a specific commercial package of 10 dose pack in 1 carton / 30 blister pack in 1 dose pack (51079-321-30) / 1 tablet, film coated in 1 blister pack (51079-321-01) of Finasteride, labeled by Mylan Institutional Inc.. This is formulated for use and contains as the active substance.

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Mylan Institutional Inc. on July 13, 2015. The current certification is valid through June 30, 2019.

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51079032156. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.